Eli Lilly and Company (LLY)
Buy, Sell, Or Hold LLY Stock At $850?
Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.
Eli Lilly and Company (LLY) Q3 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President-Investor Relations Dave Ricks - Chief Executive Officer Lucas Montarc - Chief Scientific Officer and President, Lilly Immunology Gordon Brooks - Group VP, Controller and Corporate Strategy and Interim CFO Dan Skovronsky - Chief Scientific Officer and President-Lilly Immunology Patrik Jonsson - President-Lilly Diabetes and Obesity and Lilly USA Ilya Yuffa - Executive Vice President Jacob Van Naarden - President, Lilly Oncology Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citigroup Evan Seigerman - BMO Capital Seamus Fernandez - Guggenheim Mohit Bansal - Wells Fargo Terence Flynn - Morgan Stanley Umer Raffat - Evercore ISI Steve Scala - TD Cowen David Risinger - Leerink Kerry Holford - Berenberg Chris Shibutani - Goldman Sachs Trung Huynh - UBS Courtney Breen - Bernstein Operator Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations.
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday.
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
Eli Lilly's eyewatering upsurge this year was upended by its double-slashed full-year 2024 guidance following the Q3 earnings update this morning. The slight Q3 revenue miss continues to highlight volatile supply chain dynamics facing its best-selling Zepbound/Mounjaro tirzepatide products. Investors were also caught off guard by the unprecedentedly material acquired IPR&D charge related to LLY's acquisition of Morphic Holdings in Q3.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.S. The drugmaker blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates.
Eli Lilly: The Stock Might Have Peaked
Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk — and we should be very cautious about an investment.
Why Eli Lilly Stock Is Sinking Today
The big pharmaceutical company provided a disappointing Q3 update.
Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Lilly Lowers Forecast on Weight-Loss Disappointment
Eli Lilly & Co. lowered guidance on lackluster sales of its blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro. Madison Muller reports on "Bloomberg Open Interest.
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales
Drug maker Eli Lilly's share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare misstep for the Wall Street darling.
